PEI Pharmacare
P.O. Box 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca

Programmes provinciaux de médicaments
C.P. 2000
Charlottetown, PE
C1A 7N8
www.princeedwardisland.ca

PEI Pharmacare Bulletin

Issue (2025-19) **September 9, 2025**

CRITERIA UPDATE

Effective immediately, special authorization criteria for currently listed **cabozantinib (Cabometyx)** have been amended to include the following:

Advanced or Metastatic Renal Cell Carcinoma (RCC)
For the treatment of patients with advanced or metastatic renal cell carcinoma who have received at least one prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy when used as:

- first line therapy in combination with nivolumab;
- second-line therapy following disease progression on sunitinib, pazopanib or pembrolizumab in combination with axitinib or lenvatinib; or
- third-line therapy following disease progression on immunotherapy and VEGFR TKI (i.e., sunitinib or pazopanib), used in any sequence.

Renewal Criteria:

- Written confirmation that the patient has responded to treatment and there is no evidence of clinically meaningful disease progression.

Clinical Note:

- Treatment should be discontinued upon clinically meaningful disease progression or unacceptable toxicity.

Claim Notes:

- Requests for cabozantinib will not be considered for patients who experience disease progression on everolimus or axitinib monotherapy.
- Initial Approval Period: 1 year.
- Renewal Approval Period: 1 year

Effective immediately, special authorization criteria for currently listed **olaparib (Lynparza)** have been amended to include the following:

First-Line Metastatic Castrate-Resistant Prostate Cancer

- In combination with abiraterone and prednisone for the first-line treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Clinical Notes:

- Patients should have a good performance status.
- Treatment should continue until disease progression or unacceptable toxicity.
- Eligible patients must have a confirmed germline and/or somatic BRCA1 or BRCA2 gene alteration prior to starting treatment.
- Patients should not have received prior treatment with a poly - (ADP ribose) polymerase (PARP) inhibitor, or with androgen-receptor-axis-targeted (ARAT) therapy (e.g., apalutamide, darolutamide, enzalutamide).
- Patients should not have received prior treatment with abiraterone or are within 4 months of initiating abiraterone in the mCRPC setting with no disease progression.